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http://www.springerplus.com/content/3/1/264RESEARCH Open AccessWomen’s preferences for selective estrogen
reuptake modulators: an investigation using the
time trade-off technique
Angelique F Ralph1*, Brittany Ager1, Melanie L Bell1,2,3, Ian M Collins4, Lesley Andrews6, Kathy Tucker6,
Nicole O’Reilly7, Kelly-Anne Phillips5 and Phyllis Butow1,2,8Abstract
Purpose: Selective Estrogen Receptor Modulators (SERMs) reduce the risk of breast cancer for women at increased
risk by 38%. However, uptake is extremely low and the reasons for this are not completely understood. The aims of
this study were to utilize time trade-off methods to determine the degree of risk reduction required to make taking
SERMs worthwhile to women, and the factors associated with requiring greater risk reduction to take SERMs.
Methods: Women at increased risk of breast cancer (N = 107) were recruited from two familial cancer clinics in
Australia. Participants completed a questionnaire either online or in pen and paper format. Hierarchical multiple
linear regression analysis was used to analyze the data.
Results: Overall, there was considerable heterogeneity in the degree of risk reduction required to make taking
SERMs worthwhile. Women with higher perceived breast cancer risk and those with stronger intentions to undergo
(or who had undergone) an oophorectomy required a smaller degree of risk reduction to consider taking SERMs
worthwhile.
Conclusion: Women at increased familial risk appear motivated to consider SERMs for prevention. A tailored
approach to communicating about medical prevention is essential. Health professionals could usefully highlight the
absolute (rather than relative) probability of side effects and take into account an individual’s perceived (rather than
objective) risk of breast cancer.
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A strong family history of breast cancer and/or carrying
a germline mutation in the BRCA1 or BRCA2 gene, sub-
stantially increases breast cancer risk (Antoniou et al.
2003; Pharoah et al. 1997). For example, mutation car-
riers have average lifetime risks of 65% and 45% respect-
ively (Antoniou et al. 2003), compared with 12% for the
Australian general population (Australian Institute of
Health and Welfare 2009).
Risk reduction strategies for women with an elevated risk
of breast cancer include surgery, namely bilateral mastec-
tomy and bilateral pre-menopausal salpingo-oophorectomy,* Correspondence: angelique.ralph@sydney.edu.au
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in any medium, provided the original work is pand medication such as selective estrogen receptor modu-
lators (SERMs) (Rebbeck et al. 2009; Rebbeck et al. 2004).
There is strong evidence that SERMs such as tamoxifen
and raloxifene, taken daily for 5 years, reduce breast can-
cer risk by 38% (Cuzick et al. 2013). However, uptake of
these agents is very low, even in women at high familial-
risk (Phillips et al. 2006; Savage 2007; Vogel 2010; Keogh
et al. 2009; Evans et al. 2001; Collins et al. 2013). Whilst it
has been estimated that 15% of women in the United
States aged 35 to 79 could potentially benefit from tam-
oxifen (Freedman et al. 2003), less than 0.2% of women in
this age range are taking tamoxifen (Waters et al. 2010).
The reasons for low SERM uptake are not completely
understood, although fear of side effects, difficulty com-
prehending risk and biases against taking medication, have
been shown to be important in several studies (Day et al.Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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standing how women make decisions about breast can-
cer risk management might ultimately enhance uptake.
The Time Trade-Off (TTO) method, establishes willing-
ness to trade-off quality of life for length of life and has
been widely utilized to elicit patients’ preferences in situa-
tions that involve complex trade-offs between the bene-
fits and harms of medical decisions (De Haes & Stiggelbout
1996; Duric et al. 2007; Lin et al. 2012; Simes & Coates
2001). Studies investigating patient-preferences for adjuvant-
chemotherapy in early breast cancer have found that a
surprising number of women judged negligible benefits
(0.1% to 1% increase in survival rate) sufficient to make
adjuvant-chemotherapy worthwhile (Duric et al. 2007;
Simes & Coates 2001). Parenting concerns, minimizing fu-
ture regret, doubts about information provided by health-
care professionals and feeling they had no choice were the
main explanations given by women for judging negligible
benefits worthwhile.
The present study aimed to expand on previous re-
search by exploring not only the minimum absolute risk-
reduction that women judge necessary to make initiating
SERMs worthwhile, but also the clinical and demographic
variables associated with this outcome. Based on the lit-
erature, we hypothesized that higher objective breast
cancer risk, younger age, being a parent and considering
risk-reducing surgery would all be associated with require-
ment of a lower risk reduction to make taking SERMs
worthwhile (Lovegrove et al. 2000; Tchou et al. 2004;
Jansen et al. 2004).
Methods
Participants
Eligibility criteria included: being at moderate or high
risk of breast cancer (see below), competency in English,
aged 18 to 70 years, and no personal history of breast or
ovarian cancer or bilateral mastectomy. Participants who
had previously undergone bilateral oophorectomy (which
reduces breast cancer risk if done while pre-menopausal)
were not excluded, as their residual risk is still high enough
to warrant consideration of SERMs.
Procedure
Consecutive eligible women identified from the clinic da-
tabases of two Australian Familial Cancer Clinics (FCCs)
were invited to participate by the FCC; interested women
were phoned by a researcher to gain verbal consent. Con-
senting women completed the study online or by paper
and pencil. They first completed the consent form, then
read a fact sheet that provided information on SERMs,
risk-reducing mastectomy and salpingo-oophorectomy
to ensure a basic level of knowledge, and then com-
pleted the questionnaire. Women were categorized as
at moderate or high risk of breast cancer based onfamily history and BRCA1 and BRCA2 mutation status,
using Cancer Australia definitions, that is, high risk is
greater than three times the population risk and moderate
risk is one and a half to three times population risk
(NBOCC 2009). Ethics approval for the study was obtained
from the University of Sydney and participating sites.
Measures
Demographic characteristics
We collected age, ethnicity, relationship status, parity, num-
ber of daughters, plans for future children, menopausal
status, BRCA1 BRCA2 mutation status, cigarette smoking
status, personal history of blood clots, and family and/or
personal history of bilateral mastectomy and/or oophorec-
tomy and/or SERM use.
Intention to take SERMs: patient preferences
The primary outcome, patient preferences, was assessed
using the TTO method adapted from (Simes & Coates
2001). Women were presented with hypothetical scenar-
ios and asked to decide between taking and not taking
SERMs. Women indicated if they would or would not
take SERMs if taking SERMs were to reduce their life-
time breast cancer risk from a starting risk of 50% down
to 50% (that is, not reduce their risk at all), then down
to 49.5%, to 49%, to 48%, to 45% and so-on down to 0%
by 5% increments. A second scenario was presented from
a starting risk of 20%, with SERMs hypothetically reducing
risk down to 20% (not reducing risk at all) then down to
19.5%, to 19%, to 18%, to 17%, to 15% and so-on down to
0% by increments alternating between 2 and 3%.
These two scenarios were based on the average life-
time risk of developing breast cancer for a woman at
high risk (50%) and for a woman at moderate risk (20%).
The “tipping-point”, the risk reduction required to make
taking SERMs worthwhile, was computed for each par-
ticipant for both the 50% and 20% risk scenarios by sub-
tracting the percentage where the woman crossed from
not taking SERMs to taking SERMs from the corre-
sponding baseline risk. Thus, a lower tipping point rep-
resents a lower degree of risk reduction required to
intend to take SERMs.
It was emphasized to participants that the choices were
hypothetical; there were no right or wrong answers; and
the numbers were hypothetical scenarios and did not
apply to them personally. Following the TTO, women
were asked to list, in order of importance, the three most
important factors influencing their decision to take or not
take SERMs.
Data analysis
Associations between TTO tipping points scores and clin-
ical and demographic characteristics were explored through
correlations and adjusted-analysis using multiple linear
Ralph et al. SpringerPlus 2014, 3:264 Page 3 of 9
http://www.springerplus.com/content/3/1/264regression. In order to represent the equally important
views of women who did not ‘tip’ (i.e., women who con-
sistently chose to either take or not take SERMs, regard-
less of degree of benefit), 0.5 was added to all tipping
point scores. Age and risk status were included as covari-
ates in all multiple linear regressions due to strong theor-
etical rationale (Lovegrove et al. 2000; Tchou et al. 2004).
Intention to have bilateral mastectomy and intention to
have (or having had) bilateral oophorectomy were also in-
cluded as binary covariates, as women do not consider
SERMs in isolation but rather as an addition or alternative
to other risk reduction strategies (Metcalfe et al. 2007).
As history of blood clots and smoking status were not
correlated with any of the outcomes, they were not in-
cluded as covariates. Having a daughter/s was also omitted
as a covariate as it demonstrated a large and significant
correlation of r = .70 (p < .001) with another independent
variable, parity.
Items women had listed as important in their decision-
making during the TTO were thematically analyzed. For
each woman, items were weighted from 3 to 1 from high-
est to least important, and categorized into identified
themes. A weighted-frequency score was then calculated
for each theme by summing the weightings of each item
in the theme.
As some women in the sample had previously taken
SERMs, a sensitivity-analysis was conducted to assess
the impact this variable had on each of the models.
Results
Sample
Of the 407 invitations sent, 117 women responded and
107 (26%) completed the questionnaire. Analysis com-
paring de-identified data on non-responders with that of
responders indicated that more women at moderate risk
participated (53%) than did not participate (47%) com-
pared to women at high risk (33% versus 67%) or those
who were BRCA1 or BRCA2 positive (24% versus 76%).
However as few eligible moderate risk women were identi-
fied, the absolute numbers were small. There were no
other differences identified between responders and non-
responders.
Participant characteristics are summarized in Table 1.
The mean age was 43 (SD = 10.8). Forty-one women (38%
of the sample) were BRCA1 or BRCA2 mutation positive,
56 (52%) were at high risk but without a documented mu-
tation and 10 (9%) were at moderate risk.
Tipping points
Tipping points are summarized in Figures 1 and 2. Some
women had no tipping point. Specifically, 5.4% and 9.2%
of women for the 50% and 20% baseline scenarios re-
spectively, invariably chose to take SERMs and 7.5% and
15.3% of women for the 50% and 20% baseline scenariosrespectively consistently chose not to take SERMs. There
were no significant differences in the mean tipping points
between risk groups (i.e., moderate, high, mutation posi-
tive) in either the 50%-baseline risk scenario, F(2,90) =
2.48, p = .09, or the 20%-baseline risk scenario, F(2,95) =
1.63, p = .20.
Sensitivity analysis showed that having previously
taken SERMs did not appreciably change multivariate
analysis results, therefore the results shown here include
the whole sample. As shown in Table 2, perceived risk
and intention to undergo, or has undergone oophorec-
tomy accounted for a significant amount of variance in
tipping point scores in both scenarios (R2 = .19, p = .01,
R2 = .17, p = .02 respectively). Women who intended to
undergo or had undergone oophorectomy judged smaller
amounts of risk reduction sufficient to take SERMs in
both the 50% and 20% base risk scenarios. Additionally,
women with higher perceived breast cancer risk required
a smaller degree of risk reduction for it to be worthwhile
for them to take SERMs in the 20% scenario.
Qualitative responses
Issues affecting their decision, listed by women, are sum-
marized in Table 3. The risk reduction offered by SERMs,
and one’s personal level of risk and family concerns, were
the most cited reasons for hypothetically choosing to take
SERMs. Side effects was clearly the most cited reason for
not taking SERMs, followed by low perceived efficacy of
SERMs and choosing other methods of risk reduction.
Most women (n = 53) did not specify which of the
possible side effects were influencing their decision,
however, of those who did, menopausal symptoms was
the most frequently reported (n = 10), followed by un-
known long-term consequences (n = 6), sexual function
(n = 4), fertility (n = 4), weight gain (n = 2), osteoporosis
(n = 3) and cognition (n = 1).
Discussion and conclusion
Discussion
This study is the first to our knowledge to apply the
Time Trade-Off (TTO) method to elucidate how women
at increased risk of breast cancer make decisions regard-
ing using SERMs to reduce risk. The substantial minor-
ity of women who had no tipping-point was surprising.
Six percent and 16% of women, for the 50% and 20%
baseline scenarios respectively, consistently chose to take
SERMs even when there would not be any reduction in
the risk of breast cancer. These women reported being
most influenced by: minimizing the stress and worry as-
sociated with being at increased risk; family concerns;
and lowering their risk of breast cancer. Previous re-
search has found that many women judge negligible
benefits sufficient to engage in treatment for breast can-
cer (Duric et al. 2007; Simes & Coates 2001; Heisey et al.
Table 1 Demographic and clinical characteristics of participants at moderate risk of breast cancer, high risk of breast
cancer and those with a mutation in the BRCA1 or BRCA2 gene
Variable Moderate risk High risk Mutation positive Combined
n=10 n=56 n=41 N=107
M SD M SD M SD M SD
Age (years) 41.8 10.2 44.5 11.0 41.2 10.7 43.0 10.8
n % n % n % n %
Ethnicity
Australian 4 40 45 80 30 73 79 74
European 3 30 6 11 4 10 13 12
Asian 0 0 2 4 2 5 4 4
Other 3 30 3 5 5 12 11 10
Relationship status
Single 1 10 16 29 14 34 32 30
Married/de facto 9 90 40 71 27 66 76 71
Children
Yes 5 50 11 20 16 39 32 30
No 5 50 45 80 25 61 75 70
Daughter/s
Yes 4 40 36 64 21 51 61 57
No 6 60 19 34 20 49 45 42
Want future children
Yes 4 40 10 18 8 20 22 21
No 4 40 40 71 28 68 72 67
Unsure 1 10 6 11 5 12 12 11
Menopausal status
Premenopausal 7 70 31 55 19 46 57 53
Perimenopausal 1 10 6 11 0 0 7 7
Menopausal 1 10 15 27 20 49 36 34
Unsure 1 10 4 7 2 5 7 7
Family history of prophylactic mastectomy
Yes 3 30 14 25 17 41 34 32
No 7 70 42 75 24 59 73 68
Family history of prophylactic oophorectomy
Yes 1 10 10 18 19 46 30 28
No 9 90 46 82 22 54 77 72
Family history of SERMs
Yes 5 56 26 46 10 24 41 38
No 4 44 30 54 30 73 64 60
Personal history of oophorectomy
Yes 0 0 8 14 19 46 27 25
No 10 100 48 86 22 54 80 75
Personal history of SERMs
Yes 1 10 12 21 5 12 18 17
No 9 90 44 79 36 88 89 83
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Table 1 Demographic and clinical characteristics of participants at moderate risk of breast cancer, high risk of breast
cancer and those with a mutation in the BRCA1 or BRCA2 gene (Continued)
Cigarettes per day
None 8 80 53 95 40 98 101 94
10 or less 2 20 3 5 0 0 5 5
11 to 20 0 0 0 0 1 2 1 1
History of blood clots
Yes 1 10 0 0 0 0 1 1
No 9 90 56 100 41 100 106 99
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61% of women with early stage breast cancer judged one
extra day in a life expectancy of 5-years sufficient to have
adjuvant chemotherapy, regardless of the baseline risk, of
breast cancer related death (Duric et al. 2007).
Further, many women would consider SERMs if the
benefits were sufficiently large, with 70% of moderate and
90% of high risk women respectively willing to consider
SERMs for a 40% or less risk reduction (likely realistic).
Thus general interest in SERMs in this group of moderate
and high risk women was high.
A small proportion of women consistently chose not to
take SERMs, even if SERMs reduced their risk of breast
cancer to zero. All such women listed side effects as one
of the top three important factors influencing their deci-
sion. This is congruent with previous research (Port et al.0%
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strating that women often decline to take tamoxifen because
of fear of side effects which are frequently overestimated.
Future research should explore which side effects are most
concerning to women. Perhaps women could be offered a
trial of SERMs to determine if they are substantially af-
fected by vasomotor and gynecologic side effects, before
making a decision whether to plan for 5 years of use.
Communicating absolute, rather than relative risks for ser-
ious potential side effects such as endometrial cancer and
thrombosis may also help to put these into perspective, es-
pecially for pre-menopausal women where they are rare
(Keogh et al. 2009; Harvey et al. 2011; Fisher et al. 1998).
Unlike low benefits required by most women with breast
cancer to take adjuvant chemotherapy (Duric et al. 2007),
many women in the current study required a large risk% 25% 30% 35% 40% 45% 50%
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Figure 2 Amongst women who did ‘tip’ (n = 74), cumulative proportions of women considering taking SERMs for various degrees of
risk reduction for 20% baseline scenario. Eight participants were excluded from the analysis of the 20%-baseline scenario as they switched
multiple times between taking SERMs and not taking SERMs throughout the same baseline scenario; thus a tipping point could not be calculated.
Table 2 Multiple linear regression analysis predicting
tipping point at 50% and 20% baseline risk
Dependent variable Independent
variables
B (95% CI) P-value
Tipping point at
50% baseline risk
(R2 = .19) .01
Age .05 (-.3,.4) .77
Risk status
Moderate Reference
High -6.9 (-18.3, 4.5) .23
Mutation positive -1.5 (-13.8, 4.5) .81
Has children -2.7 (-10.1, 4.8) .48
Intention to have
mastectomy
-4.2 (-11.0, 2.6) .22
Intention to have
oophorectomy
-11.7 (-18.5 ,-4.8) .001
Perceived risk -0.1 (-.15, .13) .87
Tipping point at
20% baseline risk
(R2 = .17) .02
Age .03 (-.1,.2) .72
Risk status
Moderate Reference
High -1.5 (-.6.4, 3.4) .54
Mutation positive -.1 (-5.4, 5.2) .96
Has children -.5 (-3.7, 2.7) .76
Intention to have
mastectomy
-.9 (-3.9, 2.0) .54
Intention to have
oophorectomy
-3.7 (-6.7, -.8) .02
Perceived risk -.1 (-.1, .0) .01
Regression coefficients B and 95% confidence intervals (CI) are shown.
Table 3 Categories of factors women considered most
influential in their hypothetical decision to take or not
take SERMs
Category Weighted frequencya
Incentives
Risk reduction 96
Personal risk 52
Reduce stress and worry 17
Family concerns 25
Age 2
Side effectsb 2
Barriers
Side effects 214
Other risk reduction methods 46
Inadequate efficacy 140
Taking medication 29
Age 15
Lack of information 10
Medical advice 18
Cost 14
aWeighted frequency was calculated by giving weightings of 3, 2 and 1 to
answers listed as of highest importance, of next degree of importance and of
least importance respectively. bPositive side effects were listed.
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risk scenario, over 40% of women needed the risk to be
halved to 10% in order to consider taking SERMs to be
worthwhile. Previous studies have reported that healthy
individuals with no current symptoms have a lower toler-
ance for potential toxicities. Therefore, women ‘at risk’ ra-
ther than ill may require greater potential benefit from
SERMs to outweigh the associated negative aspects and in-
crease the likelihood of choosing this risk reduction option
(Lawrence et al. 2012).
Younger age, higher objective risk and having children
produced results in the predicted direction, however,
none were significantly associated with degree of risk re-
duction required to take SERMs, for either the 20% or
the 50% baseline risk scenario. Previous studies have had
conflicting findings regarding the association between
age and acceptance of risk-reducing tamoxifen (Lovegrove
et al. 2000; Tchou et al. 2004; Bober et al. 2004; Meiser
et al. 2003). Whilst some women may decline SERMs to
avoid premature menopausal symptoms, other women
may be more influenced by the fact that the most favor-
able risk benefit ratio is seen in premenopausal women
(Harvey et al. 2011).
Women who reported that they were likely to undergo
(or had undergone) an oophorectomy required less risk
reduction in order to choose to take SERMs than women
who were not considering this procedure. It is perhaps
not surprising that women who are motivated enough to
consider surgical risk reduction may be more willing to
accept SERMs.
Subjective but not objective breast cancer risk was
predictive of the degree of risk reduction required to
take SERMs in the 20% baseline condition, with neither
predictive in the 50% baseline condition. This is con-
gruent with previous studies where subjective but not
objective risk was associated with either considering tam-
oxifen (Meiser et al. 2003) or uptake of tamoxifen (Tchou
et al. 2004; Bober et al. 2004). It is a well documented
phenomenon that women overestimate their risk of breast
cancer e.g. (Lovegrove et al. 2000; Heisey et al. 2006; Black
et al. 1995; Davis et al. 2004; Lerman et al. 1995) and that
perception of risk is rarely a direct comprehension of ac-
curately understood probability information (Bober et al.
2004; Hopwood 2000). Thus care must be taken in dis-
cussing risk with these women, as it will influence their
decision-making.
The present study has a number of limitations. It was
cross-sectional and hypothetical, thus causation cannot
be implied and it is not known whether intention to take
SERMs would translate into actual behavior. Furthermore,
women are unlikely to consider SERMs in isolation but ra-
ther as an addition or alternative to other methods of risk
reduction such as bilateral mastectomy and/or oophorec-
tomy. However, it was not feasible in the current study toexamine women’s preferences for multiple methods of risk
reduction.
The study had a relatively low response rate of 26%, al-
though data on non-responders suggests this did not re-
sult in a biased sample. Nevertheless, the relatively high
prevalence of previous SERM use in this sample, com-
pared with expected rates, (Collins et al. 2013) suggests
that the sample could have been unusual, thus results
should be generally applied with some caution. Women
who attend Australian familial cancer clinics have above-
average educational and socioeconomic levels and may
not be representative of the broader population of women
at increased risk (Meiser et al. 2000; Coyne & Anderson
1999; Coyne et al. 2000; Cull et al. 1998). Nonetheless,
findings are highly relevant to countries such as Australia,
where the vast majority of assessment and genetic-testing
of women at increased familial risk is done by a network
of Family Cancer Centers, and these women are the most
likely to be offered SERMs (Keogh et al. 2009).
Practice implications and future research
Many women at increased risk of breast cancer are in-
terested in using SERMs to reduce their risk. Health
professionals could focus on informing women about
the proven long-term benefits of SERMs and the high
quality of the underpinning evidence. As side effects rep-
resent a highly salient factor to women, and are often
overestimated, the absolute (rather than relative) prob-
ability of side effects should be highlighted. Our study
shows that individual preferences vary widely and thus a
tailored approach to medical prevention is essential, per-
haps with the assistance of a computerized decision aid
that can effectively translate reported relative benefits
and risks into absolute benefits and risks individualized
to each woman’s circumstances.
Future research should endeavor to assess women’s
preferences for SERMs in the context of other risk-
reduction methods and/or in a sample of women who
have declined surgical risk reduction procedures.
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